1
|
Kerstens VS, Fazio P, Sundgren M, Brumberg J, Halldin C, Svenningsson P, Varrone A. Longitudinal DAT changes measured with [ 18F]FE-PE2I PET in patients with Parkinson's disease; a validation study. Neuroimage Clin 2023; 37:103347. [PMID: 36822016 PMCID: PMC9978841 DOI: 10.1016/j.nicl.2023.103347] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2022] [Revised: 02/07/2023] [Accepted: 02/10/2023] [Indexed: 02/13/2023]
Abstract
BACKGROUND Dopamine transporter (DAT) PET provides higher resolution than DAT SPECT and opportunity for integrated imaging with MRI. The radioligand [18F]FE-PE2I is highly selective for the DAT, and PET measurements with this radioligand have good reliability and repeatability in patients with non-advanced Parkinson's disease. OBJECTIVES To validate [18F]FE-PE2I PET as measurement tool of longitudinal DAT changes in patients with Parkinson's disease. METHODS Thirty-seven subjects with Parkinson's disease (Hoehn and Yahr stage < 3) were included in a longitudinal PET study with [18F]FE-PE2I. DAT availability (BPND) in the caudate nucleus, putamen, sensorimotor striatum, and substantia nigra, was estimated with parametric imaging using Logan graphical analysis and cerebellum as reference region. For comparison with DAT-SPECT literature, sample size calculations for disease intervention studies were made. RESULTS Baseline and follow-up PET data (interval: 2.3 ± 0.5 years) were available for 25 patients (9 females, 16 males). Median age was 64.7 years (range 46-76); symptom duration: 3 years (0.25-14); Hoehn and Yahr stage (H&Y): 1 (1-2). Annualized DAT decline and effect size were: -8.5 ± 6.6 % and 1.08 for caudate nucleus; -7.1 ± 6.1 % and 1.02 for putamen; -8.3 ± 8.5 % and 0.99 for sensorimotor striatum; -0.11 ± 9.3 % and 0.11 for substantia nigra. The estimated minimum sample size needed for a treatment trial using [18F]FE-PE2I PET as imaging marker is 2-3 times lower than is reported in literature on [123I]FP-CIT SPECT. CONCLUSIONS Longitudinal [18F]FE-PE2I PET measurements in non-advanced PD demonstrate a striatal DAT decline consistent with previous SPECT and PET studies. No obvious changes of DAT availability were observed in the substantia nigra, indicating perhaps slower progression or compensatory changes. The effect sizes were numerically larger than reported in the literature for other DAT radioligands, suggesting that [18F]FE-PE2I might detect smaller DAT changes, and can be well used as progression marker in clinical trials.
Collapse
Affiliation(s)
- V S Kerstens
- Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm Health Care Services, Stockholm, Sweden.
| | - P Fazio
- Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm Health Care Services, Stockholm, Sweden
| | - M Sundgren
- Karolinska University Hospital, Neuro Department, Stockholm, Sweden
| | - J Brumberg
- Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm Health Care Services, Stockholm, Sweden
| | - C Halldin
- Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm Health Care Services, Stockholm, Sweden
| | - P Svenningsson
- Karolinska University Hospital, Neuro Department, Stockholm, Sweden
| | - A Varrone
- Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm Health Care Services, Stockholm, Sweden
| |
Collapse
|
2
|
Kalra D, Stroetmann V, Sundgren M, Dupont D, Schlünder I, Thienpont G, Coorevits P, De Moor G. The European Institute for Innovation through Health Data. Learn Health Syst 2017; 1:e10008. [PMID: 31245550 PMCID: PMC6516723 DOI: 10.1002/lrh2.10008] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2016] [Revised: 03/22/2016] [Accepted: 04/13/2016] [Indexed: 01/25/2023] Open
Abstract
The European Institute for Innovation through Health Data (i~HD, www.i-hd.eu) has been formed as one of the key sustainable entities arising from the Electronic Health Records for Clinical Research (IMI-JU-115189) and SemanticHealthNet (FP7-288408) projects, in collaboration with several other European projects and initiatives supported by the European Commission. i~HD is a European not-for-profit body, registered in Belgium through Royal Assent. i~HD has been established to tackle areas of challenge in the successful scaling up of innovations that critically rely on high-quality and interoperable health data. It will specifically address obstacles and opportunities to using health data by collating, developing, and promoting best practices in information governance and in semantic interoperability. It will help to sustain and propagate the results of health information and communication technology (ICT) research that enables better use of health data, assessing and optimizing their novel value wherever possible. i~HD has been formed after wide consultation and engagement of many stakeholders to develop methods, solutions, and services that can help to maximize the value obtained by all stakeholders from health data. It will support innovations in health maintenance, health care delivery, and knowledge discovery while ensuring compliance with all legal prerequisites, especially regarding the insurance of patient's privacy protection. It is bringing multiple stakeholder groups together so as to ensure that future solutions serve their collective needs and can be readily adopted affordably and at scale.
Collapse
Affiliation(s)
- D. Kalra
- Department of Public Health, Unit of Medical Informatics and StatisticsGhent UniversityGentBelgium
| | - V. Stroetmann
- Empirica Gesellschaft für Kommunikations‐ und Technologieforschung mbHBonnGermany
| | | | - D. Dupont
- Data Mining InternationalGenevaSwitzerland
| | - I. Schlünder
- Technologie‐ und Methodenplattform für die vernetzte medizinische Forschung e.V.BerlinGermany
| | - G. Thienpont
- RAMIT, Research in Advanced Medical Informatics and Telematics (vzw ‐ asbl)Ghent University HospitalGentBelgium
| | - P. Coorevits
- Department of Public Health, Unit of Medical Informatics and StatisticsGhent UniversityGentBelgium
| | - G. De Moor
- Department of Public Health, Unit of Medical Informatics and StatisticsGhent UniversityGentBelgium
| |
Collapse
|
3
|
Sundgren M, Piehl F, Wahlin Å, Brismar T. Cognitive function did not improve after initiation of natalizumab treatment in relapsing-remitting multiple sclerosis. A prospective one-year dual control group study. Mult Scler Relat Disord 2016; 10:36-43. [DOI: 10.1016/j.msard.2016.08.011] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2016] [Revised: 07/28/2016] [Accepted: 08/23/2016] [Indexed: 01/25/2023]
|
4
|
Beresniak A, Schmidt A, Proeve J, Bolanos E, Patel N, Ammour N, Sundgren M, Ericson M, De Moor G, Kalra D, Dupont D. Cost-Benefit Assessment of the Electronic Health Records for Clinical Research (EHR4CR) European Project. Value Health 2014; 17:A630. [PMID: 27202235 DOI: 10.1016/j.jval.2014.08.2251] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Affiliation(s)
- A Beresniak
- Data Mining International, Geneva, Switzerland
| | - A Schmidt
- F Hoffmann-La Roche Ltd, Basel, Switzerland
| | - J Proeve
- Bayer Healthcare, Leverkusen, Germany
| | - E Bolanos
- Eli Lilly and Company, Alcobendas, Spain
| | - N Patel
- Eli Lilly and Company (until December 2013), Windlesham, Surrey, UK
| | - N Ammour
- Sanofi-Aventis R&D, Chilly-Mazarin, France
| | | | | | | | - D Kalra
- The European Institute for Health Records (EuroRec), London, UK
| | - D Dupont
- Data Mining International, Geneva, Switzerland
| |
Collapse
|
5
|
Coorevits P, Sundgren M, Klein GO, Bahr A, Claerhout B, Daniel C, Dugas M, Dupont D, Schmidt A, Singleton P, De Moor G, Kalra D. Electronic health records: new opportunities for clinical research. J Intern Med 2013; 274:547-60. [PMID: 23952476 DOI: 10.1111/joim.12119] [Citation(s) in RCA: 157] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Clinical research is on the threshold of a new era in which electronic health records (EHRs) are gaining an important novel supporting role. Whilst EHRs used for routine clinical care have some limitations at present, as discussed in this review, new improved systems and emerging research infrastructures are being developed to ensure that EHRs can be used for secondary purposes such as clinical research, including the design and execution of clinical trials for new medicines. EHR systems should be able to exchange information through the use of recently published international standards for their interoperability and clinically validated information structures (such as archetypes and international health terminologies), to ensure consistent and more complete recording and sharing of data for various patient groups. Such systems will counteract the obstacles of differing clinical languages and styles of documentation as well as the recognized incompleteness of routine records. Here, we discuss some of the legal and ethical concerns of clinical research data reuse and technical security measures that can enable such research while protecting privacy. In the emerging research landscape, cooperation infrastructures are being built where research projects can utilize the availability of patient data from federated EHR systems from many different sites, as well as in international multilingual settings. Amongst several initiatives described, the EHR4CR project offers a promising method for clinical research. One of the first achievements of this project was the development of a protocol feasibility prototype which is used for finding patients eligible for clinical trials from multiple sources.
Collapse
Affiliation(s)
- P Coorevits
- Department of Medical Informatics and Statistics, Ghent University, Ghent, Belgium; The European Institute for Health Records (EuroRec), Sint-Martens-Latem, Belgium
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Sunesson AL, Sundgren M, Levin JO, Eriksson K, Carlson R. Evaluation of two adsorbents for diffusive sampling and thermal desorption-gas chromatographic analysis of monoterpenes in air. J Environ Monit 1999; 1:45-50. [PMID: 11529078 DOI: 10.1039/a807657j] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Tube type samplers with two different adsorbents, Chromosorb 106 and Tenax TA, were evaluated by laboratory experiments and field tests for simultaneous diffusive sampling of alpha-pinene, beta-pinene and delta 3-carene and subsequent thermal desorption-gas chromatographic analysis. No statistically significant effects of exposure time, concentrations of monoterpenes or relative humidity were found for samplers with Chromosorb 106 when running a factorial design, with the exception of the adsorption of delta 3-carene, for which some weak effects were noted. Samplers with Tenax TA were affected by the sampling time as well as the concentration for all terpenes, with a strong interaction effect between these two factors. The terpenes showed good storage stability on both adsorbents. No effect of back-diffusion was noted when using Chromosorb 106, while Tenax TA showed some back-diffusion effects. The uptake rates, in ml min-1, for the terpenes on Chromosorb 106 were 0.36 for alpha-pinene, 0.36 for beta-pinene and 0.40 for delta 3-carene. The corresponding average values on Tenax TA were 0.30 for alpha-pinene, 0.32 for beta-pinene and 0.38 for delta 3-carene. The field validation proved that diffusive sampling on Chromosorb 106 agreed well with pumped sampling on charcoal for stationary samples, while the personal samples indicated a discrepancy of 25% between Chromosorb 106 and charcoal samples. Tenax TA generally gave lower results than Chromosorb 106 in all field samples. Samplers packed with Chromosorb 106 could be used to monitor terpene levels in workplaces such as sawmills. The major advantages with this method are the sampling procedure, which is simple to perform compared to other techniques, the easily automated analysis procedure and the possibility to reuse the samplers.
Collapse
Affiliation(s)
- A L Sunesson
- Department of Chemistry, National Institute for Working Life, P.O. Box 7654, S-907 13 Umeå, Sweden.
| | | | | | | | | |
Collapse
|
7
|
Hedenmalm K, Sundgren M, Granberg K, Spigset O, Dahlqvist R. Urinary excretion of codeine, ethylmorphine, and their metabolites: relation to the CYP2D6 activity. Ther Drug Monit 1997; 19:643-9. [PMID: 9421105 DOI: 10.1097/00007691-199712000-00007] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The formation of morphine from codeine and ethylmorphine is mainly mediated by the polymorphic enzyme CYP2D6. The objective of this study was to investigate whether CYP2D6 poor metabolizers (PM) and CYP2D6 extensive metabolizers (EM) would respond differently during testing for opiate drugs of abuse in urine after intake of these drugs. Five PM and five EM of dextromethorphan were administered single oral doses of codeine (25 mg) and ethylmorphine (25 mg), and the urinary excretion of parent compounds and selected metabolites was observed for 72 hours. Analysis was performed with GC-MS after hydrolysis of the glucuronide conjugates. Selected urine samples were screened for the presence of opiates by the Abbott ADx immunoassay method. The results from one PM and one EM were excluded because of technical analytical problems. EM excreted significantly more morphine than PM after intake of both codeine (6.5% vs. 1.1% of the dose; p < 0.05) and ethylmorphine (11.0% vs. 3.0% of the dose; p < 0.05). Screening results were positive significantly longer for EM than for PM after codeine intake (mean, 33 hours vs. 17 hours; p < 0.05), and the same trend, albeit nonsignificantly, was noted for ethylmorphine (mean, 33 hours vs. 24 hours). Regardless of CYP2D6 phenotype, significantly more morphine was formed after intake of ethylmorphine than after intake of codeine (7.0% vs. 3.8% of the dose; p < 0.05). There were high correlations between dextromethorphan metabolic ratios and the ratios of codeine to morphine, ethylmorphine to morphine, norcodeine to normorphine, and norethylmorphine to normorphine (r = 0.80 to 0.92; p = 0.030 to 0.001). Although this study should be interpreted with caution because of the few subjects included and the single-dose design, it demonstrates that the CYP2D6 phenotype clearly affects the results when testing for opiates in urine after intake of codeine and ethylmorphine.
Collapse
Affiliation(s)
- K Hedenmalm
- Division of Clinical Pharmacology, Norrland University Hospital, Umeå, Sweden
| | | | | | | | | |
Collapse
|
8
|
Spigset O, Carleborg L, Mjörndal T, Norström A, Sundgren M. Carbamazepine interference in a high-performance liquid chromatography analysis for perphenazine. Ther Drug Monit 1994; 16:332-3. [PMID: 8085288 DOI: 10.1097/00007691-199406000-00017] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
9
|
Abrahamsson B, Alpsten M, Hugosson M, Jonsson UE, Sundgren M, Svenheden A, Tölli J. Absorption, gastrointestinal transit, and tablet erosion of felodipine extended-release (ER) tablets. Pharm Res 1993; 10:709-14. [PMID: 8321836 DOI: 10.1023/a:1018959732744] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
The gastrointestinal transit and tablet erosion of felodipine extended release (ER) tablets 10 mg were studied by gamma scintigraphy in eight healthy young males after administration under fasting and nonfasting conditions. Plasma concentrations of felodipine were also measured. Gastric emptying after administration together with food (mean, 3.2 hr) was slower in all subjects compared to emptying under fasting conditions (mean, 0.6 hr). The mean small intestinal transit times for the two study conditions did not differ significantly (5.1 and 4.7 hr, respectively). Tablets did not leave the colon in any subject within 14 hr after administration. Felodipine was shown to be absorbed in the colon, although the major part of the dose was absorbed in the small intestine. The absorption rate of felodipine was related to erosion of the hydrophilic matrix tablet. Tablet erosion and hence drug absorption were slower in the more distal parts of the gastrointestinal tract. Administration together with food did not significantly affect tablet erosion.
Collapse
Affiliation(s)
- B Abrahamsson
- Pharmaceutical R&D, Astra Hässle AB, Mölndal, Sweden
| | | | | | | | | | | | | |
Collapse
|
10
|
Abstract
A flow injection analysis (FIA) extraction method has been developed for the analysis of felodipine tablets in connection with dissolution rate testing. The water-soluble oxidation product of felodipine, a pyridine derivative, was extracted into chloroform and measured at 275 nm spectrophotometrically. The FIA-extraction method has been compared with the present liquid chromatographic (LC) method. The sampling rate for the FIA-extraction (60 samples h-1) is 5 times higher than for the LC method. The FIA-extraction method has a standard deviation of 1% for both standards and samples which is the same as for the LC method.
Collapse
Affiliation(s)
- L Nord
- Department of Analytical Chemistry, Royal Institute of Technology, Stockholm, Sweden
| | | | | |
Collapse
|